Form 4: Daxor Corp Chief Scientific Officer Receives Stock Grant

Daxor Corp's Chief Scientific Officer, Jonathan Adam Feldschuh, was granted 32,000 shares of common stock that vest on December 6, 2024.

Summary

• Jonathan Adam Feldschuh, the Chief Scientific Officer of Daxor Corp, received a grant of 32,000 shares of Daxor common stock.
• The shares are scheduled to vest on December 6, 2024.
• The transaction was reported on December 10, 2024.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The stock grant may serve as an incentive for the Chief Scientific Officer to continue contributing to the company's success.

Industry Context

Stock grants are a common form of compensation for executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock grants are a standard practice for executive compensation across various industries, including biotechnology and medical device companies like Daxor.
• The size of the grant is not specified in relation to industry benchmarks, but it is a common method to incentivize key personnel.

Stakeholder Impact

• The stock grant may positively impact shareholders by incentivizing the Chief Scientific Officer to contribute to the company's success.

Key Dates

Keywords

stock grant, Daxor Corp, Jonathan Adam Feldschuh, Chief Scientific Officer, equity compensation, vesting